On March 28, 2022 ATCC, the world’s premier biological materials management and standards organization, reported that it has been awarded a two-year task order, with a ceiling value of $5.6 million, by the National Cancer Institute (NCI) (Press release, American Type Culture Collection (ATCC), MAR 28, 2022, View Source [SID1234611066]). This task order is part of the Company’s existing Indefinite Delivery/Indefinite Quantity (IDIQ) contract with NCI to support the Division of Cancer Epidemiology and Genetics (DCEG) Molecular Epidemiology Assay Support (MEAS) program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the DCEG website, its mission is to "discover the causes of cancer and inform the means for prevention by conducting transdisciplinary epidemiological and genetic research." DCEG investigators rely on contract services to provide technical support for specimen collection, receipt and processing, and assistance identifying laboratories to perform state-of-the-art testing using high-quality biological specimens collected from clinical and field sites. The MEAS program provides support services for clinical studies on the genetic and other cellular events that influence the onset of different types of cancer.
"At ATCC, we are committed to supporting members of the clinical research community by providing them with the highest quality biomaterials for cancer research," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. "We know how important this is when they are designing studies to discover cancer’s genetic and environmental determinants and innovative approaches to cancer prevention. Scientific research is critical for unlocking incredible breakthroughs in global health."
Under the contract, ATCC may coordinate receipt of specimens from clinical and field sites, process fresh samples within 24 hours, and perform a broad range of state-of-the-art molecular assays to characterize the models as required. ATCC may also provide support services for the procurement, storage, and shipment of specimens to and from international and domestic specimen sites and prepare specimens for transport to testing laboratories by aliquoting, labeling, and batching, as needed.
"Through our expertise in providing standard reagents, functional testing, and biorepository operations and management, ATCC continues to support cancer research through DCEG’s clinical studies," said Joseph Leonelli, Ph.D., Senior Vice President of ATCC Federal Solutions. "We look forward to our continued relationship with NCI through the MEAS program."